FDA-USPTO collaboration initiatives should be evidence-based, prioritize innovation

The United States Patent and Trademark Office (USPTO) and the U.S. Food and Drug Administration (FDA) are in the process of considering new collaboration initiatives aimed at biopharmaceutical patents. As outlined in a recentpublic statement andwritten comments, PhRMA appreciates the agencies seeking public participation on important innovation policy issues and we strongly support the agencies stated commitment to “ensuring our innovation system strikes the appropriate balance—encouraging meaningful innovation in drug development while supporting a competitive marketplace that can promote greater access to medicines for American families.”  
Source: The Catalyst - Category: Pharmaceuticals Authors: Source Type: news